Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
There is currently no established class of dedicated Signaling lymphocyte activation molecule family member 7 (SLAMF7) agonists that are used as standalone pro-myeloma receptor agonists. The clinically relevant approach targeting SLAMF7 is elotuzumab, which is an anti-SLAMF7 monoclonal antibody. This antibody functions as an immunostimulatory engager by activating natural killer (NK) cell responses and mediating antibody-dependent cellular cytotoxicity (ADCC) against SLAMF7-positive myeloma cells. SLAMF7 remains a significant target in multiple myeloma (MM) because it is highly expressed on both normal and malignant plasma cells, including myeloma cells, while its exp…